S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)
NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

$130.91
-1.63 (-1.23%)
(As of 02:15 PM ET)
Today's Range
$130.39
$133.65
50-Day Range
$130.40
$143.74
52-Week Range
$89.04
$148.37
Volume
242,495 shs
Average Volume
839,427 shs
Market Capitalization
$13.03 billion
P/E Ratio
54.10
Dividend Yield
N/A
Price Target
$139.67

Neurocrine Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
5.9% Upside
$139.67 Price Target
Short Interest
Healthy
2.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.72mentions of Neurocrine Biosciences in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$27.21 M Sold Last Quarter
Proj. Earnings Growth
28.72%
From $4.84 to $6.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

104th out of 918 stocks

Biological Products, Except Diagnostic Industry

11th out of 151 stocks

NBIX stock logo

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock Price History

NBIX Stock News Headlines

The 5 Stocks Most Sold By Insiders This Year (NBIX)
Uncover this 2024 Hidden Gem
Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.
Uncover this 2024 Hidden Gem
Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.
Neurocrine begins phase 2 trial for depression drug
Wells Fargo Reaffirms Their Hold Rating on Neurocrine (NBIX)
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
4/19/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
1,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$139.67
High Stock Price Target
$165.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+5.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
22 Analysts

Profitability

Net Income
$249.70 million
Pretax Margin
17.60%

Debt

Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$2.57 per share
Book Value
$22.72 per share

Miscellaneous

Free Float
95,129,000
Market Cap
$13.19 billion
Optionable
Optionable
Beta
0.25
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 66)
    CEO & Director
    Comp: $1.9M
  • Mr. Matthew C. Abernethy (Age 43)
    Chief Financial Officer
    Comp: $1.04M
  • Mr. Darin M. Lippoldt Esq. (Age 58)
    Chief Legal Officer & Corporate Secretary
    Comp: $921.01k
  • Mr. Kyle W. Gano Ph.D. (Age 51)
    Chief Business Development & Strategy Officer
    Comp: $921.52k
  • Dr. Eiry Wyn Roberts M.D. (Age 59)
    Chief Medical Officer
    Comp: $1.04M
  • Dr. Jude Onyia Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $621.66k
  • Jane Sorensen
    Head of Investor Relations
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 58)
    Chief Human Resources Officer
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 59)
    Chief Commercial Officer
    Comp: $805k
  • Mr. David Warren Boyer (Age 44)
    Chief Corporate Affairs Officer

NBIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 6 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price target for 2024?

22 Wall Street analysts have issued 12-month price objectives for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $165.00. On average, they predict the company's stock price to reach $139.67 in the next year. This suggests a possible upside of 5.9% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2024?

Neurocrine Biosciences' stock was trading at $131.76 at the start of the year. Since then, NBIX shares have increased by 0.1% and is now trading at $131.83.
View the best growth stocks for 2024 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NBIX earnings forecast
.

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Wednesday, February, 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.31. The company earned $515.20 million during the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a trailing twelve-month return on equity of 12.85%. The firm's revenue was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.51%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Los Angeles Capital Management LLC (0.25%), Portman Square Capital LLP (0.00%), State of Michigan Retirement System (0.02%) and Sendero Wealth Management LLC (0.02%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBIX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners